Literature DB >> 32056532

Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer's Disease.

Win Ning Chen1, Keng Yoon Yeong1,2.   

Abstract

Scopolamine as a drug is often used to treat motion sickness. Derivatives of scopolamine have also found applications as antispasmodic drugs among others. In neuroscience-related research, it is often used to induce cognitive disorders in experimental models as it readily permeates the bloodbrain barrier. In the context of Alzheimer's disease, its effects include causing cholinergic dysfunction and increasing amyloid-β deposition, both of which are hallmarks of the disease. Hence, the application of scopolamine in Alzheimer's disease research is proven pivotal but seldom discussed. In this review, the relationship between scopolamine and Alzheimer's disease will be delineated through an overall effect of scopolamine administration and its specific mechanisms of action, discussing mainly its influences on cholinergic function and amyloid cascade. The validity of scopolamine as a model of cognitive impairment or neurotoxin model will also be discussed in terms of advantages and limitations with future insights. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Alzheimer’s disease; Muscarinic antagonist; acetylcholine; amyloid-beta plaque; cognitive dysfunction; scopolamine.

Mesh:

Substances:

Year:  2020        PMID: 32056532     DOI: 10.2174/1871527319666200214104331

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  8 in total

Review 1.  The Brilliance of the Zebrafish Model: Perception on Behavior and Alzheimer's Disease.

Authors:  Avinash Shenoy; Meheli Banerjee; Archana Upadhya; Siddhi Bagwe-Parab; Ginpreet Kaur
Journal:  Front Behav Neurosci       Date:  2022-06-13       Impact factor: 3.617

2.  Neuroprotective Effects of Myrtenal in an Experimental Model of Dementia Induced in Rats.

Authors:  Stela Dragomanova; Stoyan Pavlov; Desislava Marinova; Yordan Hodzev; Maria Cristina Petralia; Paolo Fagone; Ferdinando Nicoletti; Maria Lazarova; Elina Tzvetanova; Albena Alexandrova; Reni Kalfin; Lyubka Tancheva
Journal:  Antioxidants (Basel)       Date:  2022-02-12

3.  Protective effects of vitamin D on learning and memory deficit induced by scopolamine in male rats: the roles of brain-derived neurotrophic factor and oxidative stress.

Authors:  Fatemeh Mansouri; Hamideh Ghanbari; Narges Marefati; Zohre Arab; Hossein Salmani; Farimah Beheshti; Mahmoud Hosseini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-03-02       Impact factor: 3.000

Review 4.  Potential of Caffeine in Alzheimer's Disease-A Review of Experimental Studies.

Authors:  Piotr Londzin; Milena Zamora; Beata Kąkol; Aleksandra Taborek; Joanna Folwarczna
Journal:  Nutrients       Date:  2021-02-06       Impact factor: 5.717

Review 5.  DDA-SKF: Predicting Drug-Disease Associations Using Similarity Kernel Fusion.

Authors:  Chu-Qiao Gao; Yuan-Ke Zhou; Xiao-Hong Xin; Hui Min; Pu-Feng Du
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

6.  A Mixture of Ginkgo biloba L. Leaf and Hericium erinaceus (Bull.) Pers. Fruit Extract Attenuates Scopolamine-Induced Memory Impairments in Mice.

Authors:  Seong Min Hong; Da Hye Yoon; Mi Kyeong Lee; Jae Kang Lee; Sun Yeou Kim
Journal:  Oxid Med Cell Longev       Date:  2022-01-27       Impact factor: 6.543

7.  Chinese Herbal Extracts Exert Neuroprotective Effect in Alzheimer's Disease Mouse Through the Dopaminergic Synapse/Apoptosis Signaling Pathway.

Authors:  Qianqian Huang; Chen Zhang; Sihao Qu; Shi Dong; Qihong Ma; Ying Hao; Zimin Liu; Shanglong Wang; Haibin Zhao; Yuanyuan Shi
Journal:  Front Pharmacol       Date:  2022-02-28       Impact factor: 5.810

8.  Friedelin Attenuates Neuronal Dysfunction and Memory Impairment by Inhibition of the Activated JNK/NF-κB Signalling Pathway in Scopolamine-Induced Mice Model of Neurodegeneration.

Authors:  Marva Sandhu; Hafiz Muhammad Irfan; Shahid Ali Shah; Madiha Ahmed; Iffat Naz; Muhammad Akram; Humaira Fatima; Ayesha Shuja Farooq
Journal:  Molecules       Date:  2022-07-14       Impact factor: 4.927

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.